TTVR Eliminates Severe Tricuspid Regurgitation in Real-World Registry

Severe tricuspid regurgitation has historically been an undertreated condition, frequently associated with significant morbidity and mortality in older adults who are often poor candidates for conventional surgery [1, 2]. While surgical tricuspid valve replacement carries an operative mortality rate as high as 12 percent, many patients remain symptomatic despite optimal medical therapy [3, 4]. The emergence of transcatheter tricuspid valve replacement offers a less invasive alternative for those at high surgical risk, aiming to improve functional capacity and reduce heart failure hospitalizations [5]. Clinical guidelines emphasize the need for individualized management strategies in valvular heart disease, yet the transition from controlled trial environments to routine clinical practice remains a critical hurdle for new technologies [6]. A recent analysis of a national registry now provides essential data on how this intervention performs in a real-world setting.